Trial | Neuroprogressive & Dementia Network - NHS Tayside Research Update, Summer 2024

The best way to be considered for current or future trials is to join the 'Permission to Contact' scheme for the Neuroprogressive & Dementia Network.  This will allow the research team to access your medical records and check whether you are eligible for studies.  To find out more details please visit https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease. 

To sign up for the 'Permission to Contact' scheme, please complete the online form https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease/patient-signup-form. Alternatively you can email tay.ndntayside@nhs.scot or call 01382 423086 to have a paper form sent out.


Current available trials:

 

  • RAPSODI GD 

Remote assessment of Parkinsonism supporting ongoing development of interventions in Gaucher disease

Open to new recruits: Yes

Study Drug: No

Inclusion criteria: Anyone with a diagnosis of Parkinson’s Disease

Participating Scottish sites: Dundee

Website: https://www.parkinsons.org.uk/research/pd-frontline-identifying-genes-people-parkinsons

 

  • ABBVIE M15-741 & M15-737 

Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion

Open to new recruits: No

Study Drug: Yes: 24hour sub-cutaneous levodopa/carbidopa infusion pump 

Inclusion criteria: >30yo, idiopathic PD that is levodopa-responsive

Participating Scottish sites: Dundee

Website: https://clinicaltrials.gov/ct2/show/NCT04379050

 

  • LIPAD

LRRK2/Luebeck International Parkinson's Disease Study Protocol: Deep Phenotyping of an International Genetic Cohort

Open to new recruits: Yes

Study Drug: No

Inclusion criteria: Involved in the ROPAD study. Parkinson’s diagnosis. Healthy volunteer.

Participating Scottish sites: Dundee

 

  • PADOVA 

A Phase IIB, randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of intravenous Prasinezumab. 

Open to new recruits: No

Study Drug: Prasinezumab/placebo

Inclusion criteria: >50-85yo, PD diagnosis 6M-3yr at screening, 3m stable treatment

Participating Scottish sites? Dundee 

Website: https://forpatients.roche.com/en/trials/neurodegenerative-disorder/pd/a-study-to-evaluate-the-efficacy-and-safety-of-intraven-35605.html

 

  • LUMA 

The Luminare Study is evaluating the safety and efficacy of a study drug, as compared to a placebo, to see if it may delay the progression of Parkinson’s disease in people who are in the early stage of their condition. 

Open to new recruits: Yes

Study Drug: BIIB122/placebo

Inclusion criteria: LUMA. 30-80 years old. Diagnosed with Parkinson’s disease within the last 2 years and were at least 30 years old when you were diagnosed.

Participating Scottish sites: Dundee

Website:  https://www.parkinsonsresearchstudies.com/?utm_source=parkinsonsfoundation&utm_medium=vanity&utm_campaign=luminare&utm_term=url&utm_content=luminarepdstudiesdotcom

 

  • BIAL ACTIVATE

Safety and Tolerability of BIA 28-6156 in people with Parkinson's Disease with a pathogenic variant in the Glucocerebrosidase (GBA1) Gene

Open to new recruits: Yes

Study Drug:  BIA 28-6156

Inclusion Criteria:  Between 30-80 yrs old, diagnosis of PD in last 7 years and a genetic screening to determine if the participant will qualify for the study

Participating Scottish Sites:  Dundee

Website:  https://bial.com/com/our-research/pipeline/bia-28-6156/

 

  • CAN PDP

CANnabidiol for Parkinson’s Disease Psychosis

Open to New recruits:  Yes

Study Drug:  CBD/placebo

Inclusion Criteria:  over 40 years old, experienced symptoms of psychosis for at least 1 month, been taking PD medication for at least 1 month, 

Participating Scottish Sites:  Aberdeen, Dundee, Edinburgh

Website:  https://www.parkinsons.org.uk/research/can-pdp-cannabidiol-cbd-people-parkinsons-who-experience-hallucinations-or-delusions

 

- For further information of other research studies:  https://bepartofresearch.nihr.ac.uk/